Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00143663 · ClinicalTrials.gov registry record · Phase 3
Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 361
- Enrollment target
NCT00143663 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 361 participants.
The verdict
NCT00143663, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 361 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if patients with elevated cholesterol, but not taking any other lipid medication, could lower their cholesterol with administration of lapaquistat acetate, once daily (QD).
Interventions
- DRUG Placebo
- DRUG Lapaquistat Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 361 participants |
| Start Date | 2005-09 |
| Est. Completion | 2006-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00143663
The ClinicalTrials.gov registry entry for NCT00143663 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 361 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00143663 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00143663 about?
NCT00143663 is a clinical study titled "Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol". The purpose of this study is to determine if patients with elevated cholesterol, but not taking any other lipid medication, could lower their cholesterol with administration of lapaquistat acetate, once daily (QD).
What is the current status of trial NCT00143663?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 361 participants. The study started on 2005-09. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00143663?
The interventions under investigation include: Placebo (DRUG), Lapaquistat Acetate (DRUG).
Who is sponsoring clinical trial NCT00143663?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.